Does infliximab influence surgical morbidity of ileal pouch-anal anastomosis in patients with ulcerative colitis?
PURPOSE: Since infliximab has been approved for treatment of patients with refractory ulcerative colitis, surgeons will be increasingly faced with operating on patients who have failed therapy with this potent immunosuppressant. This study was designed to compare short-term complications in patients with ulcerative colitis who were treated with and without infliximab before colectomy. METHODS: The charts of patients undergoing ileal pouch-anal anastomosis or subtotal colectomy for refractory ulcerative colitis during the five-year period ending October 2005 were reviewed. Postoperative medical and surgical complications were assessed. RESULTS: Seventeen patients had failed infliximab treatment and 134 patients were never treated with infliximab. Ileal pouch-anal anastomosis was performed in 112 patients (74 percent) and subtotal colectomy in 39 patients (36 percent). There were no deaths. Postoperative complications were observed in 43 patients (28 percent), with no significant differe
Related Questions
- Should ileoanal pouch surgery be staged for patients with mucosal ulcerative colitis on immunosuppressives?
- DO PATIENTS WITH "SEVERE" COLITIS HAVE A HIGHER COMPLICATION RATE AFTER ILEAL POUCH-ANAL ANASTOMOSIS (IPAA)?
- Does CT influence the decision to perform colectomy in patients with severe ulcerative colitis?
